Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 18/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4162877 | 0.91 | PTGER1 (0.49) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R | |
| SCHEMBL4150124 | 0.90 | PTGER1 (0.65) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R | |
| SCHEMBL4154577 | 0.90 | PTGER1 (0.59) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R | |
| SCHEMBL4158171 | 0.89 | PTGER1 (0.66) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R | |
| SCHEMBL4154328 | 0.88 | PTGER1 (0.52) | PTGER1CYP2C9CYP3A4CYP2C19RXRG | |
| SCHEMBL4160792 | 0.88 | PTGER1 (0.61) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4160045 | 0.88 | PTGER1 (0.59) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R | |
| SCHEMBL4155047 | 0.88 | PTGER1 (0.59) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4151783 | 0.87 | PTGER1 (0.61) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4158075 | 0.87 | PTGER1 (0.63) | PTGER1CYP2C9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | PTGER1 246/4885CYP2C9 5/4885CYP3A4 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.